The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2021 | Gastroesophageal carcinoma with HER2 gene amplification

Name: Gastroesophageal carcinoma with HER2 gene amplification
Uploaded: 2021-08-27T00:00:00Z
Duration: 1 min 43 s
Description: Daniel V. Catenacci, MD, of the University of Chicago Medical Center, Chicago, IL, discusses an abstract presented at the European Society for Medical Oncology Congress (ESMO) 2021 Meeting investigating the incidence of gastroesophageal carcinoma with HER2 gene amplification. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.

Daniel Catenacci • 27 Aug 2021

ESMO 2021

Gastroesophageal Cancer Gastrointestinal Cancer

Daniel V. Catenacci, MD, of the University of Chicago Medical Center, Chicago, IL, discusses an abstract presented at the European Society for Medical Oncology Congress (ESMO) 2021 Meeting investigating the incidence of gastroesophageal carcinoma with HER2 gene amplification. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.

Disclosures

Dr Catenacci reports disclosures with Genentech/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Novartis, Gritstone, Pieris, Zymeworks, Basilea, QED, Arcus, Foundation Medicine, Pierian, Silverback Therapeutics, Servier, Blueprint Medicines, Arcus BiosciencesTempus, Guardant Health, Archer & Natera.